While several biomarkers as prognosis factors for radiotherapy have been studied such as survivin, cIAP1 and Galectin-1 [3, 7, 31–35], the role of these molecules in concurrent chemoradiation therapy (CCRT) remains to be validated, because CCRT has been the gold standard treatment for locally advanced cervical cancer since 1999 [36]. This evidence concerns the gene BIRC2 and cervical carcinoma.